HomeCompareVIVO vs MRK

VIVO vs MRK: Dividend Comparison 2026

VIVO yields 92.17% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VIVO wins by $2.76M in total portfolio value
10 years
VIVO
VIVO
● Live price
92.17%
Share price
$2.17
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2.81M
Annual income
$897,667.74
Full VIVO calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — VIVO vs MRK

📍 VIVO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVIVOMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VIVO + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VIVO pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VIVO
Annual income on $10K today (after 15% tax)
$7,834.46/yr
After 10yr DRIP, annual income (after tax)
$763,017.58/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, VIVO beats the other by $754,689.17/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VIVO + MRK for your $10,000?

VIVO: 50%MRK: 50%
100% MRK50/50100% VIVO
Portfolio after 10yr
$1.44M
Annual income
$453,732.94/yr
Blended yield
31.62%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

VIVO
No analyst data
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VIVO buys
0
MRK buys
8
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$MRK▲ Buy$1,001 - $15,0002026-02-04
Michael McCaul🏢 House$MRK▼ Sell$15,001 - $50,0002026-01-13
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-12-19
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-28
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-08-14
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVIVOMRK
Forward yield92.17%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$2.81M$56.8K
Annual income after 10y$897,667.74$9,798.13
Total dividends collected$2.49M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: VIVO vs MRK ($10,000, DRIP)

YearVIVO PortfolioVIVO Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$19,917$9,217.01$11,206$366.19+$8.7KVIVO
2$38,468$17,156.58$12,650$502.35+$25.8KVIVO
3$72,129$30,968.48$14,407$694.19+$57.7KVIVO
4$131,447$54,268.64$16,585$967.82+$114.9KVIVO
5$233,076$92,428.26$19,342$1,363.89+$213.7KVIVO
6$402,560$153,168.46$22,913$1,947.19+$379.6KVIVO
7$677,979$247,239.72$27,662$2,823.89+$650.3KVIVO
8$1,114,590$389,152.68$34,159$4,173.35+$1.08MVIVO
9$1,790,521$597,909.22$43,337$6,308.80+$1.75MVIVO
10$2,813,525$897,667.74$56,776$9,798.13+$2.76MVIVO

VIVO vs MRK: Complete Analysis 2026

VIVOStock

VivoPower International PLC, together with its subsidiaries, operates as a sustainable energy solutions company in the United Kingdom, Australia, South East Asia, and the United States. It operates through Critical Power Services, Electric Vehicles, Sustainable Energy Solutions, and Solar Development segments. The Critical Power Services segment offers energy infrastructure generation and distribution solutions, including the design, supply, installation, and maintenance of power and control systems to a range of government, commercial, and industrial customers. The Electric Vehicles segment designs and builds ruggedized light electric vehicle solutions for customers in the mining, infrastructure, utilities, and government services sectors. The Sustainable Energy Solutions segment engages in the design, evaluation, sale, and implementation of renewable energy infrastructure; and evaluates solar, battery, and microgrid solutions. The Solar Development segment engages in the origination, development, construction, financing, operation, optimization, and sale of photovoltaic solar projects. Its operation includes 12 solar projects. The company was founded in 2014 and is headquartered in London, the United Kingdom.

Full VIVO Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this VIVO vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VIVO vs SCHDVIVO vs JEPIVIVO vs OVIVO vs KOVIVO vs MAINVIVO vs JNJVIVO vs ABBVVIVO vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.